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Massive hepatic necrosis is a key event underlying acute liver failure, a serious clinical
syndrome with high mortality. Massive hepatic necrosis in acute liver failure has unique
pathophysiological characteristics including extremely rapid parenchymal cell death
and removal. On the other hand, massive necrosis rapidly induces the activation of
liver progenitor cells, the so-called “second pathway of liver regeneration.” The final
clinical outcome of acute liver failure depends on whether liver progenitor cell-mediated
regeneration can efficiently restore parenchymal mass and function within a short time.
This review summarizes the current knowledge regarding massive hepatic necrosis and
liver progenitor cell-mediated regeneration in patients with acute liver failure, the two sides
of one coin.
Keywords: massive hepatic necrosis, acute liver failure, acute-on-chronic liver failure, liver progenitor cell, liver
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Massive hepatic necrosis (MHN) denotes an extensive and diffuse necrosis spanning multiple
lobes or multiple acini in healthy or diseased liver. MHN has many synonymous terms, for
example, massive hepatic loss, acute yellow atrophy, fulminant massive necrosis, panacinar
necrosis, confluent necrosis, multilobular necrosis et al. (Kalk, 1959; Horney and Galambos, 1977;
Craig et al., 2004). Clinically, MHN is a critical event underlying acute liver failure (ALF), a
serious clinical syndrome associated with a high mortality (Sugawara et al., 2012). Besides ALF,
MHN also occurs in chronically diseased livers suffering from acute functional decompensation
(Popper and Elias, 1955), a recently recognized disease entity entitled acute-on-chronic liver
failure (ACLF). Livers of the patients recovered from ALF or ACLF demonstrate a remarkable
regenerative capacity to rapidly restore lost parenchymal cells and corresponding functions.
This pattern of liver regeneration is thought to be mediated by liver progenitor cells (LPC)
(Desmet, 2011a,b) and entitled the “second pathway of liver regeneration” to be distinguished
from the “first pathway of liver regeneration,” in which repopulation of the liver is dependent
Abbreviations: ACLF, acute-on-chronic liver failure; ALF, acute liver failure; APACHE, acute physiology score, age points,
chronic health points; HBcAg, hepatitis B core antigen; HBV, hepatitis B virus; CARS, compensation anti-inflammatory
response syndrome; CDE, choline-deficient, ethionine-supplemented; CLIF-SOFA, chronic liver failure-sequential organ
failure assessment score; DR, ductular reaction; ECM, extracellular matrix; INR, international normalized ratio; LPC,
liver progenitor cells; MELD, model for end-stage liver disease; MHN, massive hepatic necrosis; MODS, multiple organ
dysfunction syndrome; SHN, subacute hepatic necrosis; SIRS, systemic inflammatory response syndrome.
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on the remaining mature hepatocytes (Clouston et al., 2009).
Necrosis and LPC-mediated regeneration comprise two sides of
one coin, the balance of which determines the destiny of patients
suffering fromMHN.
This review discusses defining pathological features of MHN
as well as the role and potential mechanisms of LPC-mediated
liver regeneration in patients with liver failure. We mainly
focus on the knowledge gained from human studies. Table 1
summarizes the main references supporting the views expressed
in this review.
Pathological characteristics of MHN
Seventy years ago, two elegant studies investigated detailed
pathological features of MHN (Lucke, 1944; Lucke and Mallory,
1946). In these studies, Lucke and colleagues collected a wealth
of clinical data from autopsied specimens of different organs of
patients who died in an outbreak of “fatal hepatitis” in the Army
of the United States between 1942 and 1945. The two cohorts
in this series comprised of patients whose death and autopsy
time occurred either less or more than 10 days after onset of the
disease, respectively. Patients with MHN displayed the following
histological features:
(1) In patients with a clinical course of less than 10 days, the
lesion involved all parts of the liver uniformly. In many
cases, tissue destruction was extreme and complete. But it
was also frequently observed that a few hepatocytes persisted
at the lobular periphery, forming a narrow rim. In patients
with a clinical history of more than 10 days, destruction
of the liver was less uniform. The parenchyma was
completely obliterated in large areas, whereas destruction
was incomplete elsewhere.
(2) The destruction extended from terminal veins to periphery
of lobes.
(3) Dead cells were removed very rapidly. The earliest stages of
cell disintegration could not be observed. Even in the most
rapidly succumbing patients, no traces of dead cells could be
found.
(4) The destruction specifically affected hepatocytes, whereas the
framework and sinusoids remained unaltered.
(5) No scar occurred in necrotic areas.
(6) Remarkable inflammatory reaction accompanied the
destructive process. Inflammatory cellular infiltration
was considerably more marked in the acute stage (<10
days) than that in the subacute form (>10 days).
Macrophages/monocytes were the most prominent
infiltrating cells. The most conspicuous inflammation
was localized at the lobular periphery.
(7) LPC-mediated ductular reaction (DR) and regeneration
occurred at an extremely early phase of destruction and
persisted for a long time.
(8) In patients with a clinical history of more than 10 days,
endophlebitis of the efferent veins was conspicuous, whereas
the phenomenon was less common in patients with a clinical
history of less than 10 days. In these early cases, the walls
of the terminal veins were substantially thickened and of
homogenous, hyaline texture. In the latter group, fibrous
obliteration of the smaller veins was more common than
inflammatory reaction of the vessels.
(9) Jaundice and different forms of cholestasis were principal
features in MHN patients with a long-term clinical history.
However, jaundice was less common in patients with a
clinical history of less than 10 days. Figure 1 shows an
HBV patient who had undergone acute liver failure for 4
days. The liver parenchyma has been completely obliterated
(Figure 1A). Remarkable inflammatory cell infiltration into
destructive areas (Figure 1B) with endophlebitis of the
terminal veins (Figure 1C) is observed. Strong ductular
reaction can be detected at this moment (Figure 1D).
These two seminal studies, which included 296 dead patients with
autopsy (most of whom were USA soldiers), represent the most
complete and thorough investigations into MHN so far. In times
of peace, studies like these, based on multiple autopsy samples,
are no longer feasible. Thus, the findings from these two studies
remain unique and relevant even 70 years later.
Besides pathological features of MHN, Lucke’s studies also
provided impressive data on clinicopathological correlations.
One of the pivotal findings is the non-correlation between liver
lesion and clinical duration. No relationship can be established
between duration of the disease, inflammatory reaction and the
degree of liver regeneration (Lucke, 1944; Lucke and Mallory,
1946). Marked regenerationmay be present in some patients with
a short disease course, but absent in others with a long clinical
history. Similar phenomena are also observed in patients with
ACLF (Li et al., 2015).
A key issue that Lucke did not answer is whether the extent
of necrosis has a direct impact on the final clinical outcome
of patients, e.g., incidence of multiple organ failure and death.
Subsequent studies from Hanau’s and Chenard-Neu’s groups
address this question (Hanau et al., 1995; Chenard-Neu et al.,
1996). In Hanau’s study, half of the enrolled patients had
MHN (defined as parenchyma loss >90% of the entire liver),
whereas others had up to 70–90% preservation of hepatocytes.
However, survival rate was low in all patients, regardless of
parenchymal preservation. In addition, the study did not find a
correlation between the extent of necrosis and the development
of intracranial hypertension, the most common cause of death in
ALF (Hanau et al., 1995). The findings were further supported by
Chenard-Neu’s work. In a clinical study to investigate the role of
auxiliary liver transplantation in treating 30 patients with ALF,
Chenard-Neu and colleagues showed that the percentage and
distribution of necrosis at the time of transplantation was not
associated with the final outcome (Chenard-Neu et al., 1996).
In addition to patients with ALF, who have healthy livers
before disease onset, MHN also occurs in patients with cirrhosis
(Popper and Elias, 1955). In a recent clinical study, we
investigated 174 transplanted livers with HBV-related cirrhosis
(Li et al., 2015). Among them, 69 had severe necrosis between
15–90% of the entire liver. We separated patients with serious
necrosis into two groups according to area of necrosis (15–33%
or 33–90%) and compared critical clinical parameters, including
creatinine, serum total bilirubin, international normalized ratio
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TABLE 1 | Selected clinical references investigating massive hepatic necrosis and liver progenitor cell in acute or acute-on-chronic liver failure.
Authors and Time Findings Comments References
Lucke, B. (1944) and
Lucke, B. and Mallory,
T. (1946)
The two studies based on 296 dead patients with
autopsy described detailed pathological features
and clinicopathologic correlation of fatal hepatitis
(virus-induced ALF).
The most complete and thorough investigations into
MHN and pathological features of ALF so far. The
studies not only uncovered the basic pathological
features of MHN during ALF, but also pointed out
the huge difficulty in clinical investigation of MHN:
clinicians have few chances to obtain liver samples
where MHN is occurring.
Lucke, 1944; Lucke
and Mallory, 1946
Popper, H. and Elias,
H. (1955)
This study proposed that the process is similar
whether massive necrosis occurs in a previously
healthy person or in a patient with cirrhosis.
This study performed 60 years ago suggested that
ACLF has the similar pathological features as ALF.
Popper and Elias, 1955
Boyer, J. L. and
Klatskin, G. (1970)
This study showed that liver biopsy can successfully
discriminate patients with “subacute hepatic
necrosis” from those with “classic necrosis”
according to presence or absence of pan-lobular
necrosis.
Liver biopsy is a good tool to monitor MHN. Boyer and Klatskin,
1970
Hanau, C., et al. (1995) This study showed histopathological heterogeneity
in fulminant hepatic failure. In addition, the authors
proved that the percentage and distribution of
necrosis was not associated with clinical outcome.
The study reminds clinicians of the potential
misleading results of percutaneous liver biopsy due
to regional inhomogeneities.
Hanau et al., 1995
Chenard-Neu, M. P.,
et al. (1996)
This study showed that the percentage and
distribution of necrosis at the time of transplantation
was not associated with the final outcome.
The two studies (Hanau’s and Chenard-Neu’s)
suggest that the extent of MHN should not be
considered a prognostic marker of ALF.
Chenard-Neu et al.,
1996
Katoonizadeh, A., et al.
(2006)
This study proposed that 50% loss of hepatocytes
is a threshold for extensive activation of LPCs due
to a significant decrease of proliferative activity in
the remaining hepatocytes.
This impressive clinical study suggests a potential
link between severe hepatocyte death and
activation of LPC.
Katoonizadeh et al.,
2006
Liu, Q, et al. (2007) This study showed that the newly formed
hepatocytes are not yet effectively connected to the
biliary system due to marked ischemia and
obstruction of intralobular canaliculi.
The study points out a key issue in ALF: Connection
between the newly formed hepatocytes and existing
biliary tree determines whether these hepatocytes
have complete functions.
Liu et al., 2007
Farci, P., et al. (2010) This study showed that overwhelming response of
humoral immunity may play a role in MHN.
The study explores an important role of humoral
immunity in MHN.
Farci et al., 2010
Dechene, A. et al.
(2010)
This study showed a positive correlation between
parenchymal loss, LPC proliferation and HSC
activation.
The study suggests potential interactions between
LPC proliferation and activated HSCs during liver
regeneration after MHN.
Dechêne et al., 2010
Stravitz, R. T, et al.
(2011)
This study proposed a novel category of MHN
based on special characters of autoimmune
hepatitis.
This new category of MHN suggested an important
impact of etiology on the pathogenesis of MHN.
Stravitz et al., 2011
Nissim, O., et al. (2012) This study investigated expression gene profiles in 2
HBV patients who underwent MHN.
The study provides important information about
global changes of gene expression in liver tissues
after MHN.
Nissim et al., 2012
Dechene, A., et al.
(2014)
This study showed that performing liver biopsy
using mini laparoscopy in patients with ALF and
severe coagulopathy was safe. Detecting Ki67 and
M30 with IHC staining may identify patients who
would recover spontaneously or who would need a
liver transplant.
The study provides further evidence suggesting that
liver biopsy is a very useful tool in monitoring
disease progression in ALF.
Dechêne et al., 2014
Li, H., et al. (2015) This study confirmed that massive hepatic necrosis
is the pathological feature of ACLF, at least in
cirrhotic patients with HBV infection. This study also
showed that extent of necrosis did not correlate
with clinical outcome.
The study confirms Popper’s view that the process
is similar whether massive necrosis occurs in a
previously healthy person or in a patient with
cirrhosis.
Li et al., 2015
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FIGURE 1 | Pathological feature of massive hepatic necrosis. A
representative liver tissue was obtained from a patient with acute HBV
infection who had undergone liver failure for 4 days. (A) A line depicts that the
liver parenchyma had been completely destroyed. Masson staining highlights
shrinkage of the liver capsule (green color in upper limit of the tissue). (B–C)
Remarkable inflammatory cells (arrows) infiltration into destructive areas with
ductular reaction is shown. Endophlebitis of the terminal veins is highlighted by
a frame and magnified in (C) Masson staining. (D) Ductular reaction is further
confirmed at the necrotic liver using immunohistochemical staining for CK19.
(INR), disease severity scores [model for end-stage liver disease
(MELD), Child–Pugh, and acute physiology score, age points,
chronic health points (APACHE) III] and organ-failure scores
[chronic liver failure-sequential organ failure assessment score
(CLIF-SOFA), sequential organ failure assessment score (SOFA)]
at different time points before liver transplantation between both
groups. Patients with small (15–33%) or large (33–90%) areas of
necrosis had an identical clinical outcome. These results suggest
that occurrence of MHN, i.e., the event itself, rather than the
extent of necrosis, is critical in the progression of liver failure and
extrahepatic organ failure in patients with ALF or ACLF.
Massive Hepatic Necrosis: Definition and
Classification
So far, a consensus definition of MHN has not yet been agreed
upon. Massive hepatic necrosis is a morphological concept. The
core characteristic of MHN is extensive multilobular/panacinar
hepatocyte necrosis (Craig et al., 2004). MHN was previously
defined according to the extent of necrosis. For example, MHN
was defined by some experts as extensive, diffuse panlobular
(panacinar) and multilobular necrosis of >60–70% as noted
on examination of the entire liver on explant, autopsy, or
clinical visualization (Alastair et al., 2012). The term submassive
hepatic necrosis (SMHN) has sometimes been used for lesions
that involve global necrosis of 30–70% of the entire liver
(Alastair et al., 2012). In addition, Hanau and colleagues
categorized MHN when a whole liver showed nearly 100%
necrosis, whereas SMHN was termed as a liver with necrosis
of between 15 and 90% (Hanau et al., 1995). These definitions
based on the extent of necrosis are artificial. Except in autopsied
or transplanted livers, calculating necrotic percentage of the
entire liver is impossible in routine clinical practice. The key
question is whether the extent of hepatocyte necrosis affects
the clinical outcome of patients. As mentioned above, the
percentage and distribution of necrosis at the time of liver
examination is not correlated with the final clinical outcome
of patients with ALF. Thus, a rational definition of MHN is
still at large. Clinical markers and biomarkers, which reflect
patho-physiological change in the damaged liver, e.g., MHN and
regeneration, or clinical outcome of patients undergoing ALF are
missing.
Recently, an acute liver failure study group proposed a
novel category in autoimmune acute liver failure by classifying
several variants of MHN as MHN1–MHN5 (Stravitz et al.,
2011). MHN1 and MHN2 are equivalent to classic MHN and
SMHN. Bridging hepatic necrosis or multilobular necrosis with
neocholangiolar proliferation was defined as MHN3. MHN4
and MHN5 were defined as serious necrosis combined with
features of autoimmune hepatitis. This classification suggests an
important impact of etiology on the pathogenesis of MHN.
Mechanism of MHN
The mechanisms underlying MHN are largely unknown so far.
As mentioned above, massive hepatic necrosis is a traditional
morphological concept in this review. Thus, the term “necrosis”
does not denote that necrosis, a mode of cell death often
juxtaposed to apoptosis, is the major mechanism underlying
MHN. The disease progression in patients with MHN is
dramatic. The timespan between the initiation of symptoms and
death can be as little as 1 day (Lucke and Mallory, 1946). On
the other hand, the dead cells in necrotic livers are removed
very rapidly (Lucke and Mallory, 1946). These features make
investigations into the mechanisms of MHN very difficult. Thus,
the relative contribution of apoptosis or necrosis to MHN in
patients is controversial (Schulze-Osthoff and Bantel, 2011).
So far, most investigations to delineate the mechanism have
been performed in animal models (comprehensively reviewed by
Bantel and Schulze-Osthoff, 2012). Clinically, elevated levels of
death ligands or receptors, e.g., CD95L, CD95, TRAIL, TNF-α,
TNF receptors and Caspases, have been reported in ALF patients
induced by different etiologies (Strand et al., 1998; Ryo et al.,
2000; Streetz et al., 2000; Tokushige et al., 2000; Nakae et al.,
2001; Rivero et al., 2002; Volkmann et al., 2008), suggesting
an association between apoptosis and MHN in progression of
ALF. On the other hand, necrosis is considered a prominent
death pathway of hepatocytes in some drug-induced ALFs.
For example, acetaminophen metabolism leads to generation
of toxic metabolite N-acetyl-p-benzoquinone that induces loss
of mitochondrial membrane potential and depletion of ATP in
hepatocytes (Hinson et al., 2010).
More recently, necroptosis has been reported to play a critical
role in cell death during liver disease and ALF (Luedde et al.,
2014). Necroptosis is a newly discovered Caspase-8 regulated
necrotic pathway, which requires receptor interacting protein
kinase 3 (RIP3) and phosphorylated Mixed Lineage Kinase
Domain-like Protein (MLKL) (Pasparakis and Vandenabeele,
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2015). Wang and colleagues found significantly elevated levels
of phospho-MLKL in liver tissues from 14 patients with drug
induced liver injury (DILI) compared to normal liver specimens
(Wang et al., 2014). In the acetaminophen-induced mouse ALF
model, inhibition of RIP3 protein or the use of RIP3-deficient
mice strongly decreased necrotic cell death in the early phase of
liver damage, however, the protective effects was lost after 24 h
(Ramachandran et al., 2013). Further, investigations are required
to elucidate the role of necroptosis in ALF and ACLF.
It should be emphasized that most of the clinical studies to
date measured the levels of death ligands/receptors only in blood
samples. Even if some measurements were performed in liver
tissues, the time point investigators collected the samples might
be not the time hepatocytes were dying. Thus, which pathways,
apoptosis, necrosis or necroptosis, and how these pathways
contribute to MHN remains unclear. Very likely, etiology and
duration of the disease determine the nature and extent of cell
death in MHN.
Recently, Farci and colleagues investigated explanted liver
tissues from two patients with HBV-associated ALF and found
a massive accumulation of plasma cells secreting IgG and IgM
and complement deposition within necrotic areas. These results
suggest an overwhelming response of humoral immunity in ALF
(Farci et al., 2010). In addition, they found that the molecular
target of these antibodies is the hepatitis B core antigen (HBcAg)
(Farci et al., 2010). However, how and to what extent the B cell
response contributes to massive necrosis in HBV-associated ALF
needs further investigation.
Besides the mechanisms underlying MHN, a lot of other
interesting questions have not been answered yet. For instance,
why is it only hepatocytes that die during MHN? Why does the
sinusoidal framework remain intact during MHN?
Liver Progenitor Cells Mediate Liver
Regeneration in MHN
It is not clear why some individuals recover from ALF
spontaneously while others die. Although parenchymal cells are
almost completely lost in the process of MHN, the liver still
demonstrates an enormous regenerative capability to restore liver
parenchyma and function, which is thought to be dependent on
liver progenitor cells residing in the Canals of Hering and the
ductules (Gouw et al., 2011; Desmet, 2011a,b; Itoh andMiyajima,
2014). The final clinical outcome is dependent on whether the
massive parenchymal loss can be rapidly compensated by LPC-
mediated regeneration. In Lucke’s studies, “proliferative changes
in bile ducts” accompanied massive necrosis in the patients
with acute liver failure. They described that “in most cases,
even the most acute, the small twigs of the bile ducts, both
septal (perilobular) and interlobular, exhibit some evidence of
proliferation. These little ducts normally are inconspicuous.” The
“proliferative changes in bile ducts” presented as “the ducts have
irregular shapes, due to budding and branching, and the nuclei
of the component cells are deeply chromatic.” Interestingly, in
some of patients the clinical duration was less than 1 day (Lucke
and Mallory, 1946). These “proliferative changes in bile ducts”
can be attributed to activation and proliferation of LPC-mediated
ductular reaction.
Ductular reaction is defined as a reaction of ductular
phenotype, possibly but not necessarily of ductular origin, in
acute and chronic liver disease (Roskams et al., 2004). DR
may arise from different cell sources in different settings,
including (1) proliferation of pre-existing cholangiocytes; (2)
liver progenitor cells (local and/or circulating cells probably bone
marrow-derived); (3) rarely, biliary metaplasia of hepatocytes;
(4) hepatocytes (Desmet, 2011b). In MHN, LPCs are the
predominant cell source of DR because most parenchymal cells
die in this setting. In chronic liver disease with different etiologies
(for example, NASH, ASH, HBV, HCV, and hemochromatosis),
the degree of DR correlates with disease severity, e.g.,
inflammation and fibrosis (Roskams et al., 2003; Clouston
et al., 2005; Richardson et al., 2007; Weng et al., 2013; Gadd
et al., 2014; Wood et al., 2014). In these settings, occurrence
of DR is closely associated with chronic liver injury-induced
hepatocyte senescence and proliferative arrest of hepatocytes.
In contrast to mature hepatocyte derived “primary hepatic
regeneration” (Clouston et al., 2005; Richardson et al., 2007),
DR-related regeneration was considered the “secondary pathway
of liver regeneration,” which is regulated by hepatic stellate
cells, inflammatory cells such as macrophages and extracellular
matrix (Clouston et al., 2009). Multiple cytokines (IL-6 Matthews
et al., 2004, TNF-α/TWEAK Jakubowski et al., 2005, TGF-
β Nguyen et al., 2007, and IFN-γ Knight et al., 2007; Weng
et al., 2013), growth factors (HGF and EGF) (Campbell et al.,
2001), hormones (insulin and somatostatin, Jung et al., 2010,
2012), neurotransmitters (Cassiman et al., 2002), transcription
factors (NFκB Tirnitz-Parker et al., 2010), and signaling pathways
(Jak/STAT Yeoh et al., 2007, Wnt, Spee et al., 2010; Boulter et al.,
2012, Notch, Spee et al., 2010; Boulter et al., 2012; Sicklick et al.,
2006; Omenetti and Diehl, 2008; Omenetti et al., 2008, 2009) have
been recognized to regulate the process. Detailed descriptions are
provided in various reviews elsewhere (Gouw et al., 2011; Best
et al., 2013; Williams et al., 2014).
In contrast to chronic liver diseases, the regenerative process
that follows MHN has not yet been intensively investigated.
Several studies described robust DR in patients with ALF
(Katoonizadeh et al., 2006, 2010; Dechêne et al., 2010; Rastogi
et al., 2011). Katoonizadeh reported that 50% loss of hepatocytes
is a threshold for extensive activation of LPCs due to significant
decrease of proliferative activity in the remaining hepatocytes
(Katoonizadeh et al., 2006). Given that liver failure occurs within
a very short time, several factors may determine whether LPC-
dependent liver regeneration can save the failing liver, including
the number of activated cells, speed of cell proliferation, and
direction of cell differentiation.
So far, it is not clear which proportion of LPCs is activated
and how fast the LPC proliferation is proceeding in ALF. In
chronic liver disease, some studies based on animal models
reported that the activation and expansion of the LPCs requires
more than 7 days, while LPC differentiation into intermediate
hepatocyte requires another 7 days (Fausto, 2004; Fausto et al.,
2006). Obviously, LPC expansion and differentiation at such
low speed cannot rapidly restore hepatocyte mass and function
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due to MHN. Actually, in patients with MHN, “proliferative
changes in bile ducts” occurred even within 1 day after initiation
of disease (Lucke and Mallory, 1946), indicating that LPC
mobilization during MHN happens at high speed and extent.
Recently, work from Nissim and colleagues provided clues to
the potential contribution of LPCs in ALF (Nissim et al., 2012).
In this study, they investigated liver regeneration signature
in 4 liver tissues (2 with MHN and 2 with SMHN) from
patients with HBV-associated ALF and 10 donated livers from
volunteers using microarray analyses (Nissim et al., 2012). Four
patients underwent liver transplantation within 8 days from the
onset of symptoms. Compared with control livers, all patients
with ALF demonstrated highly up-regulated gene expression
associated with LPCmarkers, including CK19 and CK7, EPCAM,
CD133/PROM1, CD24, SOX9, THY1, CD44, NCAM1, and CK8.
Among 4 livers with severe necrosis, 2 livers with MHN had
much higher expression of LPC-associated genes than the other
2 with SMHN, suggesting that the MHN induces the highest
expression of LPC-associated genes.
LPCs possess bi-potential capacity, being able to differentiate
into either hepatocytes or cholangiocytes (Roskams, 2003, 2008).
Figure 2 shows the typical dual differentiation of LPC in an
HBV patient 13 days after liver failure. In the process of MHN,
whether LPCs differentiate to hepatocytes with sufficient speed
and in substantial numbers determines whether the damaged
liver can restore parenchymal mass and function (Desmet,
2011a,b). In acute and chronic liver disease, the balance between
Wnt and Notch signaling is considered a key mechanism
to steer LPC differentiation in either direction (Spee et al.,
2010; Boulter et al., 2012). Prominent Wnt signaling causes
LPC differentiation into hepatocytes whereas Notch signaling
drives LPC differentiation toward cholangiocytes. It is unknown
whether these two signaling pathways play similar roles in MHN.
Analyzing microarray data in ALF, Nissim found up-regulated
FIGURE 2 | Dual differentiation of liver progenitor cells. The presented
liver tissue was from a patient with acute HBV infection who had undergone
liver failure for 13 days. CK7 immunohistochemical staining was performed.
Four fields were selected to show that liver progenitor cells contribute to
rebuild bile ducts and hepatocytes. (A–B) Liver progenitor cell-originated bile
ducts still can be discriminated by hepatocyte-like cells inside these ducts
(black arrows). (C–D) Liver progenitor cell-derived hepatocytes are highlighted
by red arrows.
genes associated with Wnt and Notch signaling pathways,
however, key component of these pathways were not detected
(Nissim et al., 2012).
Several factors may impact on LPC differentiation into
hepatocytes in MHN, including inflammatory and fibrotic
microenvironment. Distinct from other acute and chronic liver
disease, acute liver failure occurring in either a previously normal
liver or a cirrhotic liver has a unique immune response and
inflammatory cell profile in the process of disease progression.
Early in the course of ALF, severe injury of the liver recruits
activated monocytes from circulation and bone marrow to enter
the liver. These monocytes release high levels of pro- and anti-
inflammatory cytokines simultaneously both systemic and in the
liver that induces the systemic inflammatory response syndrome
(SIRS) and compensation anti-inflammatory response syndrome
(CARS) (Possamai et al., 2010). Subsequently, imbalance of
the two opposing forces steers the immune response toward
an anti-inflammatory milieu and causes functional monocyte
deactivation, sepsis and even multiple organ dysfunction
syndrome (MODS) (Wasmuth et al., 2005). So far, no data exist
as to whether the big changes of inflammatory milieu impact
DR after MHN. It seems that in most cases DR continues to
develop with time after MHN regardless of the big changes of the
inflammatory milieu.
In addition to the inflammatory environment, wound healing
in damaged liver may significantly affect LPC-mediated liver
regeneration (Kordes and Haussinger, 2013; Kordes et al.,
2014). Wound healing does not equate to fibrosis although
both are characterized by activation of local myofibroblasts
(including hepatic stellate cells and portal fibroblasts) and
subsequent deposition of extracellular matrix (ECM) in different
organs (Wynn, 2008). Nissim’s microarray analyses revealed that
the extent of liver necrosis was correlated with a prominent
fibrogenesis gene signature (Nissim et al., 2012). Dechene’s
study also showed a positive correlation between parenchymal
loss, LPC proliferation and HSC activation (Dechêne et al.,
2010). In chronic liver damage, the relationship between
LPC proliferation and HSC activation has been intensively
investigated. In an animal model feeding a choline-deficient,
ethionine-supplemented (CDE) diet, Van Hul and co-workers
found that HSC activation and collagen deposition occurred
after 3 days of CDE feeding while LPC proliferation was
manifested after 7 days. During the progression of liver damage,
LPCs were embedded in ECM at all times (Van Hul et al.,
2009). The phenotypic orientation of LPCs in this process was
regulated by macrophages (Van Hul et al., 2011). However,
the scenario unraveled in chronic liver disease obviously does
not match that occurring in MHN. As mentioned above,
activation and proliferation of LPCs in liver with MHN occurred
rapidly (even within 1 day) (Lucke and Mallory, 1946). Under
these circumstances it is not likely that HSC activation and
ECM secretion are a prerequisite for further LPC activation.
Thus, signaling events that switch activation of LPC in MHN
may be dependent on parenchymal loss. In addition, HSC
activation and collagen deposition in this setting are more
likely a physiological repair response because there is no
scar tissue (fibrosis) occurring in necrotic areas during MHN
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(Lucke, 1944). The role and mechanisms of inflammation and
fibrosis in MHN should be intensively investigated in the
future.
Whether the newly formed hepatocytes have full biological
function depends on the connection between the canaliculi
of new hepatocytes and the existing biliary tree. However, in
most of cases the newly formed hepatocytes show ballooning
degeneration due to marked ischemia and obstruction of
intralobular canaliculi, suggesting that the newly formed
functional hepatocytes are not yet effectively connected to the
biliary system (Liu et al., 2007).
Massive Necrosis in Acute-on-chronic
Liver Failure
In addition to patients with ALF, who have healthy livers before
the disease onset, MHN also occurs in patients with cirrhosis.
In recent years, ACLF has been established as a distinct disease
entity derived from patients with cirrhosis or non-cirrhosis with
acute decompensation (Sarin et al., 2009; Canbay et al., 2011;
Jalan et al., 2012, 2014; Moreau et al., 2013). The disease is
characterized by several core clinical features, including acute
deterioration of hepatic functions, multiple-organ failure and
deranged systemic inflammatory responses (Sarin et al., 2009;
Laleman et al., 2011; Olson and Kamath, 2011; Gines et al., 2012;
Jalan et al., 2012). However, the pathological characteristics and
underlying pathophysiology of ACLF have not been completely
clarified so far (Jalan et al., 2014).
As mentioned above, we organized a prospective single-
center study recently, in which 174 patients undergoing liver
transplantation due to acute decompensation of hepatitis B
virus (HBV)-associated liver cirrhosis were investigated (Li
et al., 2015). In this study, MHN and SMHN were defined
as necrosis of more than 90% and 15–90% of the entire liver
on explant, respectively (Hanau et al., 1995). However, in this
cohort of patients, none had necrotic areas exceeding 90%.
SMHNwas identified in 69 patients with cirrhosis. These patients
demonstrated typical core clinical features of ACLF: acute
deterioration of hepatic functions, multiple-organ failure and
deranged systemic inflammatory responses. The results suggest
that massive necrosis (defined as SMHN in this study) is a
pathological feature of ACLF in cirrhotic patients with HBV
infection.
In principle, the process is similar whether massive necrosis
occurs in a previously healthy person or in a patient with cirrhosis
(Popper and Elias, 1955). However, cirrhotic livers disrupted by
interconnecting fibrous scars and distorted vessel systems also
endow some morphological features distinct from healthy livers,
although both suffer from acute decompensation and develop
into liver failure. For example, in a cirrhotic liver with massive
necrosis, necrotic areas of more than 90% of the entire liver are
rare. Microscopically, various amounts of cirrhotic nodules were
remaining in all livers with ACLF. Although detailedmechanisms
underlying these phenomena are not clarified, several factors
may be associated. As we know, massive necrosis extends from
terminal vein (zone 3) to the portal tracts (zone 1) in both healthy
livers (ALF) and in cirrhotic livers (ACLF). In ALF, the spread
of parenchyma loss is unstoppable. The necrosis can extend to
neighboring lobes and even to the entire liver within a very short
time. However, this kind of complete necrosis diffusion observed
in a previously healthy liver is impossible in a cirrhotic liver,
where fibrogenesis and vascular system remodeling has isolated
hepatic parenchyma into countless “islands” of different size
(Alastair et al., 2012). Within fibrous septa, extensive collagen
crosslinks develop, which are irreversible and not degraded by
enzymes like collagenases (Brenner, 2013). These septa serve as
“useful barriers” to prevent necrosis from spreading across the
cirrhotic liver. In addition, remodeling vascular system may also
impact the diffusion of necrosis in ACLF. In cirrhotic livers,
fibrous septa that link central veins and portal veins/hepatic
arteries establish anastomoses between two or more draining
vessels, which alter normal hepatic vasculature (Desmet, 2011b).
These fibrous vascularized septa linking central veins and portal
tracts create “a bridge too far” (Desmet and Roskams, 2003).
The direct anastomoses between afferent (hepatic artery and
portal vein) and efferent (centrolobular veins) vessels force
a fraction of the blood to bypass the lobular parenchyma
without functionally contacting between blood and hepatocytes
(Desmet, 2011b). These hepatic vascular alterations combined
with frequently occurring hepatic and portal thromboses induce
obliteration of small veins (e.g., terminal veins) and local
parenchymal extinction in cirrhotic livers (Wanless et al., 1995,
2000). Microscopically, small regions of extinction are easily
recognized by the close approximation of terminal hepatic vein
and portal tracts (Wanless et al., 2000; Alastair et al., 2012).
After establishment of cirrhotic nodules, some nodules have one
or more than two terminal veins whereas others do not even
have one. Massive necrosis usually occurs in cirrhotic nodules
containing terminal veins inside. In those cirrhotic nodules
without central veins, necrosis does not occur, at least not
in the early stage of disease. Whether these cirrhotic nodules
will also develop necrosis probably depends on whether the
necrosis in neighboring nodules is capable of breaking through
the surrounding septa.
Liver Biopsy in Monitoring MHN
Liver biopsy is a useful tool in managing patients with ALF.
Given that it is based on necrotic area of the whole liver, the
classic MHN/SMHN definition is impossible to adopt undergo
while a patient is alive and does not receive a liver transplant.
More importantly, the clinical outcome of a patient with acute
liver failure in either a previously healthy liver or in a cirrhotic
liver does not correlate with the extent of necrosis (Hanau
et al., 1995; Chenard-Neu et al., 1996). Detecting severe necrosis
rather than clarifying the degree of necrosis may be more
important for the prognosis of a patient with ALF. Boyer and
Klatskin successfully used liver biopsy to discriminate patients
with “subacute hepatic necrosis” (SHN) from those with “classic
necrosis” according to whether or not the lesion displayed pan-
lobular necrosis (Boyer and Klatskin, 1970). Biopsy identified
SHN showed great prognostic value (Boyer and Klatskin, 1970).
More recently, Dechene and colleagues used mini laparoscopy to
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perform liver biopsies in 39 patients with ALF (Dechêne et al.,
2014). They showed that liver biopsy in patients with ALF and
severe coagulopathy was safe. Further, detecting cell death and
regeneration markers such as M30 and Ki67 with IHC staining
may identify patients who may recover spontaneously or need
a liver transplant. Thus, liver biopsy is a very useful tool for
monitoring progression and prognosis of patients with acute
decompensation. If possible, performing serial liver biopsies
can provide dynamic information about disease progression
and help clinicians pay special attention to those patients
with MHN.
Besides liver biopsy, non-invasive marker(s), which can be
used to predict outcome of ALF, are required for future routine
clinical practice. However, finding useful and specific maker(s)
for ALF patients is a big challenge. An ideal predictive marker
should meet the following requirements: (1) The marker is
closely associated with one or several core patho-physiological
features of ALF, e.g., death of parenchymal cell, systemic or
local inflammation, cell regeneration; (2) It reflects the severity
of the disease; (3) It indicates the prognosis of ALF; and (4) It
helps clinicians to make a decision on if and when the patient
with ALF requires a liver transplantation. Given the complexity
of human ALF, we still do not know most of the mechanisms
by which liver cells are destroyed within short time, nor the
mechanisms by which the liver can regenerate itself within a
few hours (Samuel and Ichai, 2010). In addition, many factors,
including etiology, predisposition of individuals (such as gender,
age, genetics), hepatic, clinical, and biological status on admission
and at the peak of deterioration and others, influence disease
progression and final outcome of ALF. At the present time,
no single parameter can reflect this complexity of ALF and is
thus recognized as a routine clinical marker. Multiple prognostic
criteria, such as the King’s College Hospital (KCH) criteria
(O’Grady et al., 1989), Clichy–Villejuif criteria (Bismuth et al.,
1995) or Mayo end-stage liver disease score (MELD) (Malinchoc
et al., 2000), remain the most widely used prognostic criteria for
ALF. At the current stage, newmolecular markers probably make
best sense when incorporated into established prognostic models,
for example, CK18-M65-based MELD (Bechmann et al., 2010).
Summary
Massive hepatic necrosis in ALF and ACLF has unique
pathophysiological characters including extremely rapid
parenchymal cell death and dead cell removal. These features
result in very high mortality in patients. On the other hand,
they make it very difficult to study the underlying mechanisms.
Due to the rapid and severe course of the disease, obtaining
liver tissues undergoing MHN is almost impossible in clinical
practice. Thus, though MHN has been recognized for more than
one century, only preciously few studies with solid pathologic
data are available (Lucke, 1944; Lucke and Mallory, 1946). The
FIGURE 3 | A scheme depicting MHN and LPC-mediated regeneration in acute liver failure.
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mechanisms underlying MHN are unknown. It seems obvious
that the etiology underlying ALF or ACLF plays a key role in
MHN and liver regeneration. Acetaminophen induced necrosis
is more serious than that induced by non-acetaminophen toxins
(Bechmann et al., 2010). So far, how etiology impacts MHN in
ALF or ACLF is largely unanswered. In the future, clinical studies
involving histology data will remain very limited. Establishing
useful animal models will help hepatologists to understand the
detailed mechanisms of MHN.
Like the occurrence of MHN, LPC activation is very rapid.
However, in contrast to MHN, LPC-mediated liver regeneration
can sustain until parenchymal mass is restored completely if
the patient survives. Thus, clinical studies to investigate how
LPCs replace lost parenchymal cells are feasible. Although
recent pluripotent stem cell studies provide exciting results
in establishing the “first example of a functional human
organ from pluripotent stem cells” in vitro (Takebe et al.,
2013), clinical application is not yet conceivable in the near
future. One of the main reasons is that these engineered
hepatocytes lack real bile canaliculi (Michalopoulos et al., 2013).
Unlike these artificial hepatocytes, LPC-originated hepatocytes
are fully functional with intact polarity, where one end
maintains the link between hepatocyte canaliculi and the
biliary tree while the other surfaces link to membranes of
neighboring hepatocytes as the parenchyma fills in (Theise
et al., 2013). Thus, uncovering mechanisms of LPC activation,
proliferation and differentiation will also help us to identify
useful pluripotent stem cells to treat patients with liver
failure.
Acute-on-chronic liver failure is a recent recognized disease
entity. So far, a consensus definition of ACLF has not
been reached. Given that the disease occurs in a previously
cirrhotic liver, it is not known whether different etiologies,
e.g., cirrhotic livers due to HBV or alcoholic liver disease, will
present similar histological changes. In contrast to ALF, no
recognized animal models have been established. Mechanisms
and pathophysiology of ACLF are largely obscure. These
issues are awaiting further intensive investigation in the
future.
The following should be emphasized at the end of this review:
Massive hepatic necrosis and liver progenitor cell-mediated
regeneration are not isolated events during acute liver failure that
occurs either in healthy or in diseased liver. On the contrary,
these two phenomena happen almost simultaneously. LPC-
mediated regeneration is manifest at an extremely early phase
of destruction (Lucke, 1944; Lucke and Mallory, 1946). On the
one hand, MHN induces activation of LPCs and subsequent
regeneration. On the other hand, whether LPCs can provide
enough functional hepatocytes within a short time to restore
liver mass and function determines destiny of patients who are
suffering from ALF or ACLF. Thus, these two processes comprise
the “two sides of one coin.” Figure 3 summarizes the current view
of MHN and LPCs-mediated regeneration in ALF and the critical
issues to be addressed in the future.
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